Both bacteria and eukaryotic cells tend to deploy a number of fail-safes to guard their genome from mutations. However, genetic diversity and directed evolution are powerful means to engineer proteins with new functions and to optimize metabolic pathways for producing valuable biomolecules. Thus, it is not surprising that there's a need for faster mutagenesis rates at controllable DNA locations. In a recent issue of Nature, Halperin et al. delivered on these needs by developing a system capable of mutagenizing virtually any locus in the E. coli genome, termed EvolvR (Halperin et al., 2018) .
While there are other technologies for mutagenesis and directed evolution, EvolvR's flexibility, ease of use, and sequence specificity distinguish it from the rest. Previous technologies include XL1-Red (Greener et al., 1997) , orthogonal polymerase/plasmids (Camps et al., 2003) , multiplex automated genome engineering (MAGE) (Wang et al., 2009 ), phage-assisted continuous evolution (PACE) (Esvelt et al., 2011) , and mutagenesis plasmids (MP6) (Badran and Liu, 2015) . Of these, only MP6 is not limited by specific strain and culture requirements. Second, only MAGE allows for targeted mutations over inefficient, random mutations across the genome or a whole plasmid. Additionally, MAGE and PACE both rely on sophisticated culture apparatuses, which could complicate their use. EvolvR nicely addresses many of these limitations, which can theoretically be performed in diverse bacterial strains, can be targeted to specific genomic/plasmid loci for more efficient mutagenesis, and can continuously function without any extra equipment or exogenous input.
In designing EvolvR, the authors cleverly combined the specificity of CRISPR-Cas9 with mutagenic capability of an errorprone DNA polymerase. The CRISPRCas family of effectors represents one of the most powerful and easily programmable molecules for precisely targeting desired locations in the genome. It does this by using a guide RNA (gRNA) containing a user-defined 20-nt spacer sequence complementary to a specific genomic region. Most commonly, the wild-type S. pyogenes Cas9 nuclease is used, which induces a double-strand DNA break at the location specified by the gRNA. However, the authors used a variant (nickase Cas9, or nCas9) where the RuvC nuclease domain was mutated, causing the enzyme to only introduce single-stranded nicks, thus preventing toxicity due to doublestrand breaks. The second component of the EvolvR system is an error-prone polymerase (PolI3M) directly fused to nCas9. PolI3M contains three point mutations that increase its misincorporation rate and remove its proofreading activity. The authors demonstrated the fusion between the two components biases PolI3M's activity toward the genomic locus specified by nCas9, as opposed to any nicked DNA encountered in the genome.
Mechanistically, nCas9 is first recruited to the specified genomic locus and generates a break in the single strand of DNA complementary to the gRNA (Figures 1A and 1B) . After this, nCas9 dissociates, allowing PolI3M to associate at the nick site ( Figure 1C ). PolI3M then polymerizes a new DNA strand, occasionally introducing errors, and displaces the old DNA strand ( Figure 1D ). Before dissociating, PolI3M's flap endonuclease domain cleaves the original displaced strand, leaving a ligatable nick ( Figure 1E ) that the host bacteria seals after PolI3M dissociates ( Figure 1F ). Depending upon where mutations are introduced, EvolvR can possibly re-target and continuously evolve the same locus.
In its first iteration, EvolvR achieved a 24,500-fold increase in mutation rate compared to wild-type E. coli at the targeted locus. The authors made further improvements to the system by introducing three mutations to nCas9 (enhanced nCas9, enCas9) that increased its dissociation rate, thereby increasing the chance that PolI3M would associate with the DNA (Figures 1B and 1C) . Recognizing that PolI3M's processivity (15-20 nt) was a limiting factor, the authors fused it to the thioredoxin-binding domain (TBD) from the T7 bacteriophage, which has been shown to increase processivity for PolI. With these changes, the authors detected mutation rates up to 212,000-fold over wild-type and processivity up to 56 nt away.
As a proof of concept, the authors used EvolvR to target two genes in E. coli: the ribosomal protein subunits rspE and rspL. Both have known mutations that confer resistance to the antibiotics spectinomycin and streptomycin, respectively. EvolvR was able to generate mutant strains resistant to spectinomycin or streptomycin by targeting rspE and rspL individually and to both antibiotics by simultaneously evolving both genes. Additionally, the authors found novel mutations to rspE that also conferred resistance to spectinomycin, establishing that EvolvR can be used for generating new protein variants.
While EvolvR can conceivably be used in any strain of bacteria, the authors tested its use in E. coli strains and it may require further optimization for use in pathogenic or gut commensal bacteria species. To broaden EvolvR's targetable space, which may be limited by the number of S. pyogenes Cas9 PAM sites (NGG), this technology can be adapted to use other natural and engineered Cas9 or Cas12 variants with different PAM specificities (Nishimasu et al., 2018) . Finally, it remains to be demonstrated whether EvolvR can be used in eukaryotic cells, whose complex genome architecture and DNA replication/repair pathways may necessitate further engineering of the system. EvolvR is a powerful tool for easily mutagenizing specific loci and represents a marked improvement over existing technologies in terms of ease of use, precision, and flexibility, advantages that enable many new exciting applications. For example, researchers can combine directed evolution, which was awarded the Nobel Prize in Chemistry this year, with EvolvR to readily generate a library of functional variants for genes such as cytochrome p450 or even Cas9 itself. Perhaps even more exciting is EvolvR's potential for surveying the functional landscape of non-coding elements in the genome, such as promoters, enhancers, and non-coding RNA genes. By mutating coding and non-coding elements, EvolvR can also be used to rapidly engineer biosynthetic pathways that typically require rigorous optimization for boosting product yield (Galanie et al., 2015; Paddon et al., 2013) . Outside of bioreactors, microbes are being used as living drugs in the human microbiome, but face a number of challenges with the harsh environment of the gut (Riglar and Silver, 2018) . Genome-wide screening with EvolvR may allow for the enrichment of strains with enhanced survivability in the gut. Overall, EvolvR is a broad technology amenable to a number of applications and is poised to evolve how mutagenesis and directed evolution are performed. 
